Only Australian residents with severe eosinophilic asthma who have been prescribed Fasenra® (benralizumab) by their healthcare professional are eligible to enrol in and continue their participation in the Connect 360 Patient Support Program (“Program”). If enrolment is for a patient prescribed Fasenra® for a paediatric indication, and the patient is under 18 years of age, as the legal, parent/carer/guardian you give consent for them to be enrolled in the Program.
The Program offers a range of healthcare, wellness and treatment logistics services. Involvement in the Program is designed to complement and support the prescribing instructions of your healthcare professional, who is responsible for prescribing Fasenra®. This is a complementary service offered by AstraZeneca Pty Ltd. The Program does not replace the advice of your Prescribing Specialist or other healthcare professionals. You should speak to your Prescribing Specialist if you have any questions or concerns about your treatment. If you want more information about Fasenra®, or for medical information enquiries or to report an adverse event or product quality complaint, telephone 1800 805 342 or via http://contactazmedical.astrazeneca.com.
The information and resources contained in this website and correspondence from the website, are presented for information purposes only. The content is in no way intended to replace professional medical care or the attention of a qualified healthcare professional. Website content should not be used as a basis for diagnosis or choice of treatment.
The website contains information that was believed current as of the date of inclusion in the website. While we may periodically update or correct information in this website, we make no representation or warranty as to its accuracy, and we disclaim any obligation to update this information.
All of the services offered as part of the Program are optional allowing you to opt into all or just a selection of the services provided. You may opt out of any part of this program at any time by contacting the Connect 360 Clinical Liaison (1800 370 722; support@www.www.connect360asthma.com.au). If you opt out of this Program, we may still need to hold the information collected from you as part of the Program for purposes permitted by law including reporting purposes. To the extent we retain any personal information it will be handled in accordance with the Program Privacy Policy.
AstraZeneca reserves the right to cease funding the Program and/or terminate the Program with reasonable notice at any time. AstraZeneca reserves the right to change and/or cease providing any of the services within the Program with reasonable notice at any time. For more information on AstraZeneca’s Privacy Policy, go to www.astrazeneca.com.au/privacy-policy.html.